Article ; Online: Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?
Current oncology (Toronto, Ont.)
2023 Volume 30, Issue 6, Page(s) 5795–5806
Abstract: Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing ... ...
Abstract | Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing treatment approach in order to reduce the risk of local recurrence (LR), including invasive LR, which carries a subsequent risk of breast cancer mortality. However, reliable and accurate individual risk prediction remains elusive and RT continues to be standardly recommended for most women with DCIS. Three molecular biomarkers have been studied to better estimate LR risk after BCS-Oncotype DX DCIS score, DCISionRT Decision Score and its associated Residual Risk subtypes, and Oncotype 21-gene Recurrence Score. All these molecular biomarkers represent important efforts towards improving predicted risk of LR after BCS. To prove clinical utility, these biomarkers require careful predictive modeling with calibration and external validation, and evidence of benefit to patients; on this front, further research is needed. Most trials do not incorporate molecular biomarkers in evaluating de-escalation of therapy for DCIS; however, one-the Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk DCIS (ELISA) trial-incorporates the Oncotype DX DCIS score in defining a low-risk population and is an important next step in this line of research. |
---|---|
MeSH term(s) | Female ; Humans ; Carcinoma, Intraductal, Noninfiltrating/diagnosis ; Carcinoma, Intraductal, Noninfiltrating/genetics ; Carcinoma, Intraductal, Noninfiltrating/therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/therapy ; Breast Neoplasms/diagnosis ; Risk ; Biomarkers, Tumor/genetics ; Overtreatment |
Chemical Substances | Biomarkers, Tumor |
Language | English |
Publishing date | 2023-06-13 |
Publishing country | Switzerland |
Document type | Journal Article ; Review |
ZDB-ID | 1236972-x |
ISSN | 1718-7729 ; 1198-0052 |
ISSN (online) | 1718-7729 |
ISSN | 1198-0052 |
DOI | 10.3390/curroncol30060433 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 4305: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.